|
Keynote Speakers
Title to be announced
Benjamin F. Cravatt, PhD
Professor and Co-Chair, Department of Molecular Medicine
The Scripps Research Institute
Research Field: Chemical Biology
B.S., Biological Sciences, B.A., History, Stanford University
Ph.D., The Scripps Research Institute
Close window Activity-based proteomics – Protein and Ligand Discovery on a Global Scale
Title to be announced Addressing Preclinical Toxicity – Approaches and Lessons Learned
Peter Dragovich received a B.S. in chemistry from UC Berkeley and subsequently obtained a Ph.D. in synthetic organic chemistry from Caltech under the direction of Professor Andrew Myers. He has worked in the pharmaceutical industry for more than 20 years in both large-pharma and biotech organizations and has performed a variety of research and management activities during that time. He joined Genentech in 2010 and has since worked on multiple projects in both the immunology and oncology therapeutic areas. He is currently a Staff Scientist in the Discovery Chemistry Department and leads the company’s efforts to identify novel payloads and linkers that can be utilized for the creation of new antibody-drug conjugates.
Close window Mechanism-Based Toxicities Associated With NAMPT Inhibition and Related Mitigation Strategies
Axel Pähler holds a position as Expert Scientists and Pharmacokinetics, Dynamics & Metabolism (PDM) Leader at Roche Pharma Research and Early Development, pRED in Basel, Switzerland. Following his university degree in chemistry, Dr. Pähler received a Ph.D. in toxicology at the Department of Toxicology, University of Würzburg. He then trained as a Postdoc in biochemical toxicology at the Nestlé Research Center in biomarker research, drug metabolism and mass spectrometry. Over his career as Head of Drug Metabolism at Roche and as PDM Leader he contributed to the science in the field of drug metabolism related to drug safety. Dr. Pähler has a passion for bridging cross-disciplinary sciences in the area of DMPK and safety in support of drug discovery and development.
Close window Overcoming Drug Bioactivation in Lead Optimization: Case Studies
Douglas Thomson currently holds a position at Cellzome, A GSK Company in Heidelberg, Germany. He obtained his PhD in organic chemistry from the University of Strathclyde in Glasgow, UK and subsequently joined the High throughput Chemistry Department of BayerCropScience in Frankfurt, Germany as a PostDoc. Before joining Cellzome in 2011, Douglas was a medicinal chemist at the Institute of Cancer Research and Elara pharmaceuticals. At Cellzome, the focus of his research is on the utilization of mass spec driven proteomics to determine a molecules off-target profile in the context of preclinical toxicology assessments.
Close window Utilizing in Depth Understanding of a Molecules Off Target Profile to Tailor Clinical and Preclinical Safety Assessments Advances in Lead Generation
Monika is working as project leader in Discovery Chemistry at Evotec (UK). She obtained her education at the Technische Universität Wien (TU Vienna) and her PhD from the University of Liverpool. After joining Evotec in 2001, she has led medicinal chemistry teams on hit-to-lead, fragment-based and lead-optimization projects across a number of target classes and therapeutic areas. Her current research projects have a strong focus on phenotypic drug discovery and target deconvolution.
Close window A Chemist’s Guide to Modern Phenotypic Drug Discovery
Dr. Eva Martin received a Doctorate in Organic Chemistry from the University of Salamanca in 2001. She acquired additional expertise in different synthetic methodologies with short-term assignments in the Organic Chemistry Department of the Universities of London, Warwick and Cologne. In May 2001 she joined Lilly Forschung in Hamburg as a medicinal chemist and in September 2002 she moved to Lilly Alcobendas in Spain. During her career Dr. Eva Martin has made important contributions to projects in oncology, cardiovascular and endocrine areas. With strong expertise in lead generation, her interests are fragment based drug design and the development and implementation of new technologies in drug discovery with the aim to deliver faster and better clinical candidates for the unmet medical needs.
Close window ADAS (Affinity Directed Automated Synthesis): A New Technology to Accelerate Lead Generation
Dr. Sanne Schrøder Glad is a principal scientist and project manager in Nuevolution and was part of the first pioneering team developing the Chemetics technology. She has been deeply involved in designing the libraries and building the compound collection at Nuevolution. Since 2010 she has been heading several lead discovery projects both in collaboration with big pharma companies and internal of which the RORγt program is the most progressed. Before joining Nuevolution, she was research scientist at Novozymes. She has a ph.d. in computational chemistry from University of Southern Denmark.
Close window From Multiple Hit Series to (Pre)Clinical Candidates Using DNA Encoded Library Technology Advances in Synthetic Methods
Varinder K. Aggarwal studied chemistry at Cambridge University and received his Ph.D. in 1986 under the guidance of Dr. Stuart Warren. After postdoctoral studies (1986-1988) under Prof. Gilbert Stork, Columbia University, he returned to the UK as a Lecturer at Bath University. In 1991 he moved to Sheffield University, where he was promoted to Professor in in 1997. In 2000 he moved to Bristol University where he holds the Chair in Synthetic Chemistry. He was elected Fellow of the Royal Society in 2012.
Close window Assembly Line Synthesis
Thorsten Bach obtained his education at the University of Heidelberg and at the University of Southern California (USC). He received his Ph.D. in 1991 from the University of Marburg with M. T. Reetz and did post-doctoral work with D. A. Evans at Harvard University. He completed his Habilitation at the University of Münster in 1996, moved to the University of Marburg as an associate professor in 1997 and was appointed to the Chair of Organic Chemistry I at the Technische Universität München (TUM) in 2000. He is an elected member of the German Academy of Sciences (Leopoldina) and of the Bavarian Academy of Sciences.
Close window Photochemical Reactions en route to Structurally Complex Molecules
Ilan Marek, FRSC was born in Haifa (Israel), educated in France, and received his PhD thesis in 1988 from the University Pierre et Marie Curie, Paris, (France). In 1989, he was postdoctoral fellow in Louvain-la-Neuve (Belgium) and obtained a research position at the CNRS in France in 1990. After obtaining his Habilitation in Organic Chemistry, he moved to the Technion- Israel Institute of Technology at the end of 1997 where he currently holds a full Professor position. Since 2005, he holds the Sir Michael and Lady Sobell Academic Chair. He is particularly interested in developing carbon-carbon bond forming as well as carbon-carbon bond activation processes, which efficiently create multiple stereocenters in a single-pot operation. Understanding of reaction mechanisms gives insight into the origins of chemo- and stereoselectivity, and governs optimization towards the most efficient and general protocols for his methodologies. His vision is that we should provide an answer to challenging synthetic problems but it has to be coupled with unique efficiency and elegance.
Close window Small Ring Chemistry Alternative Modalities
As Vice President and Head of Chemistry and Immunology at Moderna, Dr. Matthew Stanton leads nucleotide and delivery chemistry as well as basic platform immunology in support of mRNA therapeutics discovery.
Prior to joining Moderna, Dr. Stanton was Director and head of RNA medicinal chemistry at Merck, spending 16 years in roles of increasing leadership, including small molecule program leadership and head of chemistry capabilities enhancement. He was involved in numerous therapeutic areas including oncology, cardiovascular, neuroscience and infectious disease that spanned a range of modalities including small molecules, siRNA and peptide conjugates.
Dr. Stanton graduated from Virginia Tech with a B.S. in chemistry and earned his Ph.D. in chemistry from the University of North Carolina at Chapel Hill with a focus on physical organic chemistry and natural product synthesis.
Close window Messenger RNA as A Novel Therapeutic Approach
Dr. David Tellers received his PhD from Berkeley under the guidance of Professor Robert G. Bergman. In 2001, he joined Merck working in both the Department of Chemical Engineering and Process Research where he focused on route development, catalysis, and automation. He made contributions to multiple programs, including Emend ™, Januvia ™, Cordaptive ™, and Vaniprevir ™. In 2008, he transferred to the Department of Medicinal Chemistry where he has had the opportunity to lead groups focused on oligonucleotide and peptide therapeutic development, early and late stage neuroscience and infectious disease programs, and chemical biology. He is a Director in the Discovery Chemistry Modalities Group and currently leads the recruiting efforts for Medicinal Chemistry.
Close window Discovery Chemistry Modalities: Chemistry on the Macromolecular Scale
Eric Valeur obtained his PhD from the University of Edinburgh (Prof. Mark Bradley) and then joined the Northern Institute for Cancer Research in Newcastle working as Postdoctoral Fellow on inhibitors of MDM2-p53 in Prof. Roger Griffin’s group. Subsequently, he led medicinal chemistry teams first at Merck-Serono in Paris and then at Novartis in Basel. In particular, he was involved in the development of non-peptidic proteases inhibitors within the Expertise Protease Platform. In 2014, he joined AstraZeneca in Sweden, as Associate Director for New Modalities Medicinal Chemistry. His vision is to integrate chemical spaces, in essence leveraging the potential of each modality either separately or as hybrids. He also established and steers a unique approach to innovation consisting of a Satellite Unit based at the Max Planck Institute in Dortmund, Germany, with three AstraZeneca scientists being directly embedded within Prof. Herbert Waldmann’s research group.
Close window New Modalities for Challenging Targets in Drug Discovery Challenges and Opportunities in Fragment Based Drug Discovery
Drug Discovery for Challenging Targets by X-ray Crystallographic Fragment Screening
Professor Rod Hubbard has been an academic at York for over 35 years working with methods for analysis and exploitation of protein structure. He developed molecular graphics and modelling methods in the 1980s and helped build Structural Biology at York during the 1980s and 1990s. He worked on the structure of many proteins of therapeutic importance combined with studies of protein-ligand interactions and methods in structure-based design. In 1997, he was a founding SAB member of what became Vernalis. Since 2001 he has split his time between Vernalis (fragment and structure based drug discovery) and York (fragment methods for chemical biology and industrial biotechnology). In addition, he works with UK Research Councils and consults with pharmaceutical and technology companies around the world.
Close window The Impact of Fragments on Drug Discovery
Dr Mairi Sime is currently a Staff Scientist and Chemistry Project Leader for the Beatson Drug Discovery Group at the Beatson Institute for Cancer Research in Glasgow. She obtained her degree (2000) and PhD (2004) at the University of Glasgow (Prof. Richard Hartley). Following her PhD she joined the Neurology and GI CEDD in GlaxoSmithKline in 2004 where she worked as a medicinal chemist on a number of neuropathic and inflammatory pain targets. Since joining the Beatson Drug Discovery Group in 2010 she has led medicinal chemistry teams on fragment based drug discovery projects with the aim of translating the basic biology research from the Beatson Institute and other CRUK Centres into the oncology drugs of the future.
Close window Title to be announced Chemical Biology in Drug and Target Discovery
Kai Johnsson is Director at the Max Planck Institute for Medical Research, Department of Chemical Biology since 2017. His current research interests focus on the development of chemical approaches to visualize and manipulate biochemical activities in living cells. His past achievements include the introduction of methods to specifically label proteins in living cells (i.e. SNAP-tag and CLIP-tag), the development of new fluorescent probes and sensors as well as the characterization of mechanism of actions of drugs and drug candidates. Kai Johnsson is Associate Editor of ACS Chemical Biology since 2005 and member of the Editorial Advisory Board of Science. He is co-founder of Covalys Biosciences, Spirochrome, Quartet Medicines and Lucentix.
Close window Biosensors for Measuring Metabolite and Drug Concentrations in Living Cells Late Stage Functionalization
Title to be announced
Darren J. Dixon is Professor of Chemistry at the University of Oxford. He obtained his BA, MA and D. Phil (supervised by Professor Stephen Davies) from the University of Oxford. After a postdoctoral appointment with Professor Steve Ley FRS he was appointed to the Staff of the Department of Chemistry, University of Cambridge in 2000. In 2004 he took a Senior Lectureship at The University of Manchester and was promoted to Reader in 2007. In 2008, he moved to his current position at Oxford where he is also the Knowles-Williams Tutorial Fellow in Organic Chemistry at Wadham College and the Director of the EPSRC Centre for Doctoral Training in Synthesis for Biology and Medicine. His research is centered on the development of new catalyst-enabled synthetic methodologies and their application to the synthesis of structurally complex scaffolds, natural products and molecules of biological significance. His honors include an EPSRC Leadership Fellowship, the RSC Catalysis in Organic Chemistry Award, the AstraZeneca Research Award and Novartis Chemistry Lectureship.
Close window Catalytic Approaches to Simplifying Synthesis
Title to be announced |
EFMC Sponsored Event
Media Partners
|
